Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22204230 | 1.00 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22204235 | 0.94 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22204237 | 0.94 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22204219 | 0.88 | PIK3CD (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22204220 | 0.88 | PIK3CD (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22441018 | 0.86 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22441017 | 0.86 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL22204275 | 0.85 | PIK3CD (0.64) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL22204276 | 0.85 | PIK3CD (0.64) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL22204260 | 0.85 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-10-01 | — | — | US | disclosed |
| EP-3515910-B1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PDPK1 | PIK3CG 2/4885PIK3CD 1/4885PIK3CA 6/4885 |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | PIK3CD, PIK3CB, PIK3CA | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 3/4885 |
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PRKCG | PIK3CG 2/4885PIK3CD 1/4885PIK3CA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.